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ABSTRACT
Sarcomas are rare and heterogeneous mesenchymal 
tumours of soft tissue or bone, making them prone to 
late diagnosis. In other malignancies, early diagnosis has 
an impact on stage of disease, complexity of therapeutic 
procedures, survival and health- related quality of life 
(HRQoL). Little is known about what length of diagnostic 
interval should be considered as delay in patients with 
bone (BS) or soft tissue sarcomas (STS). To quantify 
total interval (deined as time from irst symptom to 
histological diagnosis) and its components, identify 
contributing factors to its length and determine the impact 
on patients’ outcome in terms of mortality and HRQoL. A 
systematic review was conducted according to Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses guidelines. Seventy- six articles out of 2310 met 
the predeined inclusion criteria. Total intervals, varied 
broadly; 9–120.4 weeks for BS and 4.3–614.9 weeks for 
STS. Older age and no initial radiological examinations 
were contributing factors for a long interval in BS, while 
in STS results were conlicting. The impact of length of 
total interval on clinical outcomes in terms of survival and 
morbidity remains ambiguous; no clear relation could be 
identiied for both BS and STS. No study examined the 
impact on HRQoL. The length of total interval is variable in 
BS as well as STS. Its effect on outcomes is contradictory. 
There is no deinition of a clinically relevant cut- off point 
that discriminates between a short or long total interval. 
Prospero: CRD42017062492.
IntroduCtIon
Sarcomas are a rare group of solid malig-
nant mesenchymal tumours, which comprise 
more than 70 histological subtypes. They 
have considerable heterogeneity with respect 
to age of onset, anatomic location, tempo of 
progression and outcome. Approximately 
80% of sarcomas originate in soft tissue, the 
remainder in bone. Sarcomas form a typical 
example of rare cancers, with an estimated 
European incidence averaging 4–5 per 100 
000 per year.1 Patients with rare cancers 
have a higher mortality rate than those with 
common cancers because of delays to accu-
rate diagnosis and subsequent suboptimal or 
inadequate treatment, fewer developments in 
novel therapies and reduced opportunities to 
participate in clinical trials.2
Early and accurate diagnosis of cancer is 
important to optimise patient outcomes in 
terms of local disease control, overall survival 
and health- related quality of life (HRQoL).3 4 
The absence of a typical and uniform sarcoma 
presentation, the lack of public awareness, 
and the limited experience of primary and 
secondary healthcare professionals with 
sarcomas can result in a prolonged total 
interval and late referral to specialist sarcoma 
centres. The total interval is the time between 
first symptoms and (preferably histological) 
diagnosis(figure 1).5 To date, the impact of 
late referrals on sarcoma patient outcomes 
has been understudied and reports have been 
contradictory.
To inform interventions that shorten the 
total interval, better insights are needed into 
the determinants of each component of the 
total interval, such as sociodemographic, clin-
ical, psychological and healthcare factors. 
The aim of this systematic review is to examine 
the total interval of sarcoma patients by quan-
tifying its length, identifying contributing 
factors and determine the impact on patients’ 
outcome in terms of mortality and HRQoL.
MaterIal and Methods
search strategy
We conducted a systematic review according 
to Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses guidelines.6
A computerised search of the litera-
ture through PubMed (1946–present), 
MEDLINE (1950–present), EMBASE (1974–
present), Web of Science (1945–present) and 
Cochrane Library was carried out with the 
help of a librarian of the Radboudumc by two 
researchers (vs and OH) on 28 February 2019. 
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Figure 1 Time intervals in the route from irst symptom until start of treatment. Adapted from Olesen et al5 2009. Total 
interval: from irst symptom to diagnosis; patient interval: from the date the patient irst noticed a sarcoma- related symptom 
until the irst presentation to a doctor with this symptom; Diagnostic interval: from irst presentation to a doctor until diagnosis; 
primary care interval: from irst presentation to a general practitioner until irst referral to secondary care (if applicable) or to 
a specialist sarcoma centre; secondary care interval: from referral to secondary care until referral to tertiary care (a specialist 
sarcoma centre); tertiary care interval: from referral to a specialist sarcoma centre until the date of (histological) diagnosis.
The search strategy combined terms related to ‘sarcoma’, 
‘delayed diagnosis’, ‘early diagnosis’ or ‘referral’. The 
search string is presented in online supplementary mate-
rial A.
selection criteria
Studies were included if they met the following criteria: 
(1) study participants had a proven diagnosis of sarcoma; 
(2) the total interval or any of its components as defined 
in figure 1 were available and (3) the full- text paper was 
available in English. Reviews were excluded because they 
did not contain original data and single case reports were 
excluded to limit selection bias.
deinition
The following definition was used: the total interval, 
defined as time between first symptoms and (histological) 
diagnosis, which includes both a patient and diagnostic 
interval; the latter can be further divided into a primary, 
secondary and tertiary care interval. The intervals and 
their associated time points are illustrated in figure 1. 
This figure was adapted from Olesen et al5 7 by adding a 
tertiary interval, consistent with centralised sarcoma care 
pathways.
data extraction and synthesis
Study design, inclusion period, study population, length 
of total interval and its components, and effect of total 
interval on outcomes, such as metastases at diagnosis, 
overall survival and HRQoL, were extracted from 
included articles. Factors influencing length of total 
interval or its components were extracted and organised 
as tumour- specific factors (eg, histology), patient specific 
(eg, age) or healthcare related (eg, available imaging 
studies). Based on our clinical experience, previous 
reports and different healthcare providers treating these 
groups of patients, we expected to find different results 
for bone sarcoma (BS) and soft tissue sarcoma (STS), and 
data were thus presented in separate tables. Due to the 
heterogeneity of inclusion criteria and methods, it was 
not possible to conduct a meta- analysis, so results were 
reported descriptively.
results
Included articles
Our search yielded 2304 unique hits. The reference lists 
of relevant articles were searched for additional studies 
which resulted in six additional publications versus and 
OH screened titles and abstracts of these 2310 publica-
tions, 109 studies met the inclusion criteria. After careful 
independent full- text screening by versus and OH, 62 
studies were included in this review. The flow chart of this 
selection procedure is presented in figure 2.
Bone sarcomas
Length of total interval
Thirty- four studies involving a total of 17 258 patients 
investigated the total interval in BS (table 1)8–41; five of 
these studies prospectively collected follow- up data. A 
broad range in the length of the total interval was found, 
which varied from 9 to 120.4 weeks.
Components of the total interval
The impact of patient intervals was measured in 19 
studies (mean 4.1–34.1 weeks), eight studies measured 
the primary care interval (mean 5–32.3 weeks), whereas 
the secondary (mean 2.3–7.1 weeks) and tertiary care 
intervals (mean 2–17.4 weeks) were measured in two and 
three studies respectively (table 1).
Open access
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Figure 2 Selection procedure. BS, bone sarcoma; STS, soft tissue sarcomas.
Effect of tumour-speciic factors
Several factors were studied as determinants of the length 
of the total interval. Interestingly, tumour- specific factors 
such as tumour size or grade did not appear to influence 
the length of total interval.22 26 27 41 Patients with sarcomas 
located in the trunk were shown to have a longer interval 
than those who have sarcomas in the extremities (29 vs 14 
weeks; p<0.001) by Lawrenz et al (n=1792).41
Tumour histology was found to be of influence on the 
total interval. Goedhart et al performed a retrospective 
study among 102 patients with high- grade BS and reported 
a significantly longer patient interval and secondary care 
interval for chondrosarcoma versus Ewing sarcoma and 
osteosarcoma,21 which resulted in a significantly longer 
total interval, with a mean of 98.3 weeks for chondrosar-
coma, versus 22.9 and 23.3 weeks for Ewing sarcoma and 
osteosarcoma, respectively.
Four other studies reported similar results on total inter-
vals for Ewing sarcoma and osteosarcoma; all had a trend 
towards a longer diagnostic pathway for patients with 
Ewing sarcoma.12 14 26 40 In a study by Widhe et al (n=106), 
the longer diagnostic pathway in Ewing sarcoma was a 
result of both a longer patient and primary care compo-
nent12 whereas a study by Sneppen et al (n=124), reported 
a four times longer diagnostic interval for Ewing sarcoma 
than for osteosarcoma patients despite similar patient 
intervals.26 Lawrenz et al illustrated that intermediate- 
grade tumours had a longer diagnostic interval (52 weeks) 
compared with high- grade BS (12 weeks; p<0.001).41 In 
contrast, a study focusing only on BS of the foot (n=32) 
presented opposite results: a median total interval of 32.3 
weeks for chondrosarcoma, vs 64.5 weeks and 77.4 weeks 
for osteosarcoma and Ewing sarcoma, respectively.15 
Another small study (n=6) reported that half of patients 
with osteosarcoma of the foot had a considerable patient 
delay, resulting in a mean total interval of 120.4 weeks.16
Effect of patient-speciic factors
Gender was not associated with the length of the 
total interval in four studies,12 26 39 40 however, there 
was evidence that patient age was a factor. Six studies 
reported a significantly longer total interval for older 
teenagers, adolescents or adults compared with younger 
children or (younger) teenagers (<12 vs ≥12–22 years1122; 
<20 vs ≥20–86 years26; <22 vs ≥22 years27; 0–14 vs 15–19 
vs 20–29 years40; <12 versus ≥12 years11). Furthermore, 
Desandes et al found young adults were more at risk for 
a longer total interval than patients in puberty (15–19 vs 
20–24 years; 10.1 vs 21.4 weeks respectively; p=0.04).35 
Lawrenz et al (n=1792) investigated age (mean 30.7 years) 
as a continuous variable and reported every additional 
year of age was associated with a 1.3 weeks longer total 
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Table 1 Diagnostic intervals in bone sarcoma
Author;
year
Study design, inclusion period 
and country Study population Age (years)
Patient interval in 
weeks
Primary care interval in 
weeks
Secondary 
care interval 
in weeks
Tertiary care 
interval in 
weeks
Diagnostic 
interval in 
weeks
Total interval in 
weeks
Kammerer 20128 Retrospective 1972–2010
Germany
36 osteosarcoma of jaw 33.9
(2-81)*†
15.9 (4.3–103.2)*† NR NR NR NR NR
Pan
20109
Retrospective 2003–2008
Malaysia
30 osteosarcoma 
around the knee joint
17
(9-34)*†
10 (0–49)*† 5* 5 (0–24)*† 2* NR 17 (4–55)*†
Widhe
201010
Retrospective 1980–2002
Sweden
106 chest wall 
chondrosarcoma
57* 12.9 (0–507.4)‡† 19.35 (0.43–847.1)‡† NR NR NR 34.4 (4.3–
855.7)‡†
Goyal
200411
Retrospective 1990–2002
UK
103 bone sarcoma 15 (4–22)‡† 4.3‡ NR NR NR 6.88‡ 16.34 (4.3–
197.8)‡†
Widhe
200713
Retrospective 1981–2000
Sweden
26 Ewing sarcoma of 
the rib
16 (6–26)‡† 10.75 (0–43)‡† 12.9 (0–43)‡† NR NR NR NR
Widhe
12
Retrospective 1983–1995
Sweden
102 osteosarcoma 15.8 (5.5–29.5)*† 6 (1–26)*† 9 (1–52)*† NR NR NR 15 (2–75)*†
47 Ewing sarcoma 15.4 (2.5–26.0)*† 15 (1–100)*† 19 (1–72)*† NR NR NR 34 (3–150)*†
Guerra
200614
Retrospective 1985–2001
Brazil
198 osteosarcoma 15.7* NR NR NR NR NR 22.6*
55 Ewing sarcoma 12.8* NR NR NR NR NR 34.8*
Brotzmann 201315 Retrospective 1969–2008
Switzerland
32 bone sarcoma of 
the foot
NR NR NR NR NR NR 43‡
15 chondrosarcoma NR NR NR NR NR NR 32.3‡
9 osteosarcoma NR NR NR NR NR NR 64.5‡
8 Ewing sarcoma NR NR NR NR NR NR 77.4‡
Biscaglia
199816
Retrospective 1983–1999
Italy
12 osteosarcomas of 
the foot
33
(17-64)*†
50%§ NR NR NR NR 120.4 (6–48)*†
Bacci
199917
Retrospective 1979–1997 Italy 618 Ewing sarcoma NR 13* NR NR NR 4* 18*
Bacci
200019
Retrospective 1983–1999
Italy
965 high- grade 
osteosarcoma of the 
extremity
NR 5.2* NR NR NR 4.8* 10.5 (1–59)*†
810 localised 6.0* NR NR NR NR 10.7*
155 metastasized 
disease
4.1*
(p<0.00017)
NR NR NR NR 9.0*
(p<0.016)
Bacci
200218
Retrospective 1980–1999
Italy
1071 high- grade 
osteosarcoma of the 
extremity
<15: n=501¶
≥15: n=570¶
NR NR NR NR NR NR
891 localised disease   NR NR NR NR NR 10.9*
180 metastasized 
disease
  NR NR NR NR NR 9.3* (p<0.0002)
Bacci
200720
Retrospective 1983–2006
Italy
888 Ewing sarcoma 
family tumour
<12: n=160¶
≥12: n=728¶
NR NR NR NR NR 75%§
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Author;
year
Study design, inclusion period 
and country Study population Age (years)
Patient interval in 
weeks
Primary care interval in 
weeks
Secondary 
care interval 
in weeks
Tertiary care 
interval in 
weeks
Diagnostic 
interval in 
weeks
Total interval in 
weeks
Goedhart
201621
Retrospective 2000–2012
The Netherlands
102 high- grade bone 
sarcoma
30.0
(5-89)*†
NR NR NR NR NR NR
19 chondrosarcoma   34.9* (p<0.05) 28.2* 7.1* (p<0.05) 5* NR 98,3*
29 Ewing sarcoma 5.9* 14.8* 2.3* 3.5* NR 22.9* (p<0.01)
54 osteosarcoma 6.4* 8.3* 2.4* 3.8* NR 23.3* (p<0.01)
Brasme 201422 Prospective 1988–2000
France
436 Ewing sarcoma 12‡ NR NR NR NR NR 10‡
Kim
200923
Retrospective 1985–2005
Korea
26 osteosarcoma and 
doctor delay >45 days
30.2 (4–67)*† NR NR NR NR 45.2* NR
Simpson
200524
Retrospective 1965–2005
Scotland
19 Ewing sarcoma of 
upper limb
19 (3–57)*† 25.8 (4.3–774)‡† NR NR NR 5 (1–128)‡† 35 ‡
Wurtz
199925
Retrospective 1975–1995
USA
68 bone sarcoma of 
pelvic girdle
41 (8–82)‡† NR NR NR NR NR 433
25.8 (4.3–
206.4)‡†
Sneppen
198426
Retrospective 1962–1979
Denmark
84 osteosarcoma 28 (8–86)*† 6.9* NR NR NR 7.3* 27.5 (8.6–
154.8)*†
40 Ewing sarcoma 17 (2–62)*† 6.5*   32.3* 41.3 (4–206.4)*†
Nandra
201527
Retrospective 1985–2010
UK
2360 bone sarcomas 22‡ NR NR NR NR NR 16 ‡
Vadillo
201128
Retrospective 1952–2007
Peru
135 bone sarcomas of 
the jaw
31 (1–80)*† 13* 19.7* NR 17.4* NR 50.1*
Ashwood
200329
Prospective 1997–1998
UK
100 tumour service 36.3* 63.6 (0–111.8)*† NR NR NR 58 (2,3–
516)*†
NR
49 malignant disease: 
47 sarcoma
NR 32.7 (2.2–47.3)*† 32.3 (0–55.9)*† NR NR NR NR
George
201230
Retrospective 2011
UK
107 sarcoma of which ≥18* 4.3‡ NR NR NR 13.7‡ NR
41 bone sarcoma 6.5 (0–3096)‡† 16.8 (1.5–211.6)‡† NR NR NR NR
Martin
200731
Retrospective 2001–2003
USA
235 patients; 22.2 (15–29)*† NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR 10.7*
66 with sarcoma NR 20.3*
30 bone sarcoma NR 15.7*
Smith
201132
Prospective 1985–2009
UK
2568 bone sarcomas 25‡ NR NR NR NR NR 16‡
Grimer
200633
Prospective 1986–2006
UK
1460 bone sarcoma NR NR NR NR NR NR 16‡
Lawrenz
201841
Retrospective 1990–2014
UK
bone sarcoma:
1446 non- metastatic
346 metastatic
30.7* NR NR NR NR NR 16‡
45.8* vs
29.9*
Table 1 Continued
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Author;
year
Study design, inclusion period 
and country Study population Age (years)
Patient interval in 
weeks
Primary care interval in 
weeks
Secondary 
care interval 
in weeks
Tertiary care 
interval in 
weeks
Diagnostic 
interval in 
weeks
Total interval in 
weeks
Balmant
201840
Retrospective 2007–2011
Brazil
1257 osteosarcoma 
and Ewing sarcoma
0-29¶ NR NR NR NR NR NR
0-14¶ (46%) NR NR NR NR 1.1‡ NR
15–19¶ (33%) NR NR NR NR 1.3‡ NR
20–29¶ (21%) NR NR NR NR 1.9‡ NR
Bielack
200239
Retrospective 1980–1998 
German/Austrian/Swiss
1702 high- grade 
osteosarcomas
16.7† NR NR NR NR 9.9‡ NR
Chen
201734
Retrospective 2004–2012
USA
364 malignancies of 
which
30 bone sarcoma
16.5‡ NR NR NR NR NR 12.4‡
Desandes
201835
Retrospective 2012–2013
France
993 malignancies of 
which
48 bone sarcoma
NR NR NR NR NR NR NR
15–19 (n=33)¶ NR NR NR NR NR 10.1‡
20–24 (n=15)¶ NR NR NR NR NR 21.4‡
Petrilli
200636
Prospective 1987–1996
Brazil
209 high- grade 
osteosarcomas
14 (2.4–24.5)*† NR NR NR NR NR 18.4*
Yang
200937
Retrospective 1994–2005
Hong Kong
51 osteosarcoma 13 (3–20)‡† 4.3 (0–51.4)‡† NR NR NR 3 (0–50)‡† 8.7 (0–51.6)‡†
Younger
201838
Retrospective 2015
UK
558 sarcoma of which
140 bone sarcoma
64.1 (18–96)*† 56.7%§ NR NR NR NR NR
*Mean.
†Range within brackets.
‡Median.
§% of delays attributed to this interval.
¶Included age group.
NR, not reported.
Table 1 Continued
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interval (p<0.00).41 In contrast Guerra et al (n=253) found 
no significant relationship between age (range 0–30 
years) and the length of the total interval.14 Younger et al 
found no relationship between age and patient interval 
nor diagnostic interval.38
The presenting symptom did not predict the length 
of the total interval in four studies.12 13 22 26 Study results 
(n=4) on the influence of pain symptoms on the total 
interval are contradictory, with some studies suggesting a 
shortening of the interval, no influence or even a longer 
total interval.12 13 22 26
Effect of healthcare system-related factors
The influence of the year of first presentation was studied 
in five studies. None showed evidence of shortening 
total intervals over the past 30–50 years,1014 22 26 41 despite 
advances in healthcare models including the introduc-
tion of cancer pathways and dedicated specialist sarcoma 
centres.
The location of first presentation to a healthcare 
professional was investigated among patients with Ewing 
sarcoma. The diagnostic interval was significantly longer 
when presenting to a general practitioner (GP) compared 
with the accident & emergency department (p=0.04).11
The influence of radiology and pathology investiga-
tions on the diagnostic interval were reported in two 
studies.10 12 When no imaging studies were ordered at 
the patient’s first contact with a healthcare professional, 
a longer diagnostic interval was observed. When imaging 
was incorrectly interpreted as normal, which was the case 
in 35% of patients with chondrosarcoma at non- specialist 
centres, this resulted in an even longer diagnostic interval 
(21 vs 9.5 months). At non- specialist centres, only 26% 
(n=39) of chondrosarcomas biopsied were correctly diag-
nosed as malignant, while at specialist sarcoma centres, 
94% (n=34) were correctly diagnosed.10 A descriptive 
study by Ashwood et al highlighted how imaging studies 
performed prior to referral to a specialist centre often 
had to be repeated because they did not provide all 
the required information, and biopsies or surgeries 
performed by the referring teams often complicated the 
patient’s subsequent management.29
A qualitative study in Malaysia by Pan et al (n=30) 
demonstrated the multifactorial nature of diagnostic 
delay, which was dependent on the patient perception 
of symptoms and complaints, the influence of traditional 
healers and the proximity of health clinics.9 A Brazilian 
study with 1257 BS patients found differences in diag-
nostic intervals between geographic regions, possibly 
explained by the availability of CT scan equipment and 
the difference in number of hospital beds per region.40
Relationship between total interval and outcomes
The influence of delay on clinical outcomes of BS patients 
has been investigated in 20 of the 34 included BS studies 
(table 2).10 11 15 17–25 27 28 31 33 36 37 39 41
In 12 of these studies (n=7414), no significant associ-
ation between length of the total interval (mean total 
interval between 8.7 and 50.1 weeks) and overall survival 
was found.11 15 19 21 22 25 27 28 33 36 37 39 However, one of these 
studies (n=1702) found that patients with a longer total 
interval more often had metastatic disease at diagnosis 
than those with a short total interval.39
One study of 965 high- grade osteosarcomas of the 
extremities diagnosed between 1983 and 1999, identified 
an inverse relationship between the total interval and the 
stage of disease19; the patient interval was significantly 
shorter in patients with metastatic disease compared 
with patients with localised disease (4.1 vs 6.0 weeks), 
ultimately resulting in a shorter total interval (9.0 vs 10.7 
weeks). The total interval was significantly shorter in 
patients who later relapsed than in patients who remained 
free of disease after 5 years. However, this difference lost 
significance when patients were analysed according to 
disease stage at presentation. In a secondary analysis of 
this patient population, including patients diagnosed 
between 1980 and 1983 (n=1071),18 patients with a diag-
nostic interval <2 months were significantly more likely 
to have metastases at diagnosis than those with a longer 
interval (56.1% vs 45.2%; p<0.0009).
Two other studies by the same research group in 
patients with Ewing sarcoma and Ewing sarcoma family 
of tumours (ESFT), both demonstrated that a diagnostic 
interval <2 months was associated with an increased like-
lihood of metastases at diagnosis (table 2),17 20 impact on 
overall survival was not reported.
A study with 1792 BS patients showed that a longer 
duration of symptoms was associated with longer survival 
(HR 0.996, 95% CI 0.994 to 0.998).41 This continuous 
association was lost when patients were compared in cate-
gories (<or >4 months; HR 0.935 95% CI 0.743 to 1.177).
In contrast, four studies with a combined number of 
386 patients with chondrosarcoma, osteosarcoma and 
Ewing sarcoma, and mean total intervals between 10.7 
and 35 weeks, reported a negative impact of a long total 
interval on stage and survival.10 23 24 31
No study has reported on the association between 
length of the total interval on patient- reported outcomes 
including HRQoL.
soft tissue sarcoma
Length of total interval
Thirty- six studies investigated the total interval for STS 
(table 3).27 30–35 38 42–69 A combined total of 16 845 patients 
were included and, reflecting STS heterogeneity, the 
total interval varied tremendously; between 4.3 and 614.9 
weeks.
Components of the total interval
Eleven studies examined the length of one or more compo-
nents of the total interval.30 38 44 47 50–52 54 58 59 63 Patient 
intervals varied between a median of 1.3–17.2 weeks, the 
primary care interval lasted 0.1–13.3 weeks, the secondary 
care interval varied between 1.1 and 6.9 weeks and the 
tertiary care interval was 2.1–7.9 weeks.
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Table 2 The effect of diagnostic interval on stage or metastases at diagnosis, or overall survival (OS) for bone sarcomas
Author;
year
Study design, 
inclusion period and 
country Study population Age (years)
Total interval in 
weeks
Stage of disease or metastases at 
diagnosis OS
Widhe
201010
Retrospective
1980–2002
Sweden
106 chest wall chondrosarcoma 57* 34.4 (4.3–855.7)†‡ NR Patients who died from 
chondrosarcoma had interval >8 
months (p<0.05)
Goyal
200411
Retrospective
1990–2002
UK
103 bone sarcoma 15 (4–22)†‡ 16.34 (4.3–197.8)†‡ NR No association
Brotzmann
201315
Retrospective
1969–2008
Switzerland
32 bone sarcoma of the foot NR 43† No association No association
Bacci
199917
Retrospective
1979–1997
Italy
618 Ewing sarcoma NR 18 ‡ Stage: no association
Interval <2 months, more metastases (32 
vs 12% p<0.0001)
  
Bacci
200019
Retrospective
1983–1999
Italy
965 high- grade osteosarcoma 
extremity
NR 10.5 (1–59)*‡ NR No association
Bacci
200218
Retrospective
1980–1999
Italy
High- grade osteosarcoma 
extremity
891 localised disease
<15: n=501§ ≥15: 
n=570§
10.9* 45.2% diagnostic interval <2 months NR
180 metastasized disease 9.3* (p<0.0002) 56.1% diagnostic interval <2 months 
(p<0.0009)
  
Bacci
200720
Retrospective
1983–2006
Italy
888 Ewing sarcoma family tumour <12: n=160§
≥12: n=728§
<2 months: n=215§ 35.5% metastatic disease NR
≥2 months: n=658§ 15.9% metastatic disease
(p<0.0001)
NR
Goedhart
201621
Retrospective
2000–2012
The Netherlands
19 chondrosarcoma 30.0
(5–89)*‡
98.3* Metastatic disease
10.5%
5 years OS
60.9%
29 Ewing sarcoma 22.9*
(p<0.01)
37.9% 49%
54 osteosarcoma 23.3* (p<0.01) 24.1% 67%
Brasme
201422
Prospective
1988–2000
France
436 Ewing sarcoma 12† 10† No association No association
Kim
200923
Retrospective
1985–2005
Korea
26 osteosarcoma and doctor 
delays >45 days
30.2 (4–67)*‡ NR NR 5 years OS: 26%
10 years OS: 10%
Simpson
200524
Retrospective
1965–2005
Scotland
19 Ewing sarcoma of upper limb 19 (3–57)*‡ 35† A higher Enneking stage resulted in 
greater mortality (p=0.02)
NR
Wurtz
199925
Retrospective
1975–1995
USA
68 bone sarcoma of pelvic girdle 41 (8–82)*‡ 43‡ No association No association
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Author;
year
Study design, 
inclusion period and 
country Study population Age (years)
Total interval in 
weeks
Stage of disease or metastases at 
diagnosis OS
Nandra
201527
Retrospective
1985–2010
UK
2668 bone sarcoma 22† 16† No association No association
Vadillo
201128
Retrospective
1952–2007
Peru
135 bone sarcoma of the jaw 31 (1–80)*‡ 50.1* NR No association
Martin
200731
Retrospective
2001–2003
USA
30 bone sarcoma 22.2 (15–29)*‡ 15.7* Osteosarcoma: diagnostic interval 259 
days longer for patients with advanced 
stage disease than those with localised 
disease (p<0.01)
NR
Grimer
200633
Prospective
1986–2006
UK
1460 bone sarcoma NR 16† NR No association
Lawrenz
201841
Retrospective
1990–2014
UK
Bone sarcoma
1446 non- metastatic
346 metastatic
30.7* 16† No association Non- metastatic cohort: longer 
interval, better survival (HR 0.996). 
No association >or < 4 months.
45.8* vs
29.9*
P=0.009
Bielack
200239
Retrospective
1980–1998
German/Austrian/Swiss
1702 high grade osteosarcoma 16.7* 9.9† Longer diagnostic interval: more primary 
metastases (p=0.007)
No association
Petrilli
200636
Prospective
1987–1996
Brazil
209 high grade osteosarcoma 14 (2.4–24.5)*‡ 18.4* No association No association
Yang
200937
Retrospective
1994–2005
Hong Kong
51 osteosarcoma 13 (3–20)†‡ 8.7 (0–51.6)†‡ No association No association
*Mean.
†Median.
‡Range within brackets.
§Included group.
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Table 3 Length of diagnostic intervals for STS
Author;
year
Study design, time period 
and country
Study
population Age (years)
Patient
interval (weeks)
Primary
care
interval 
(weeks)
Secondary 
care
interval 
(weeks)
Tertiary 
care 
interval 
(weeks)
Diagnostic interval 
(weeks) Total interval (weeks)
Gofman
200761
Retrospective 1991–2004
Israel
73 synovial sarcoma 38 (8–82)*† NR NR NR NR NR 77.4 (8.6–202.1)*†
Amant
200362
Retrospective 1990–2002
Belgium
6 endometrial stromal sarcoma 34* NR NR NR NR NR 614.9 (103.2–1754.4)*†
Nakamura
201163
Retrospective 2001–2009
Japan
100 STS, referred for additional 
resection
57 (0–89)‡* 12.9 (4.3–
309.6)*†
NR NR NR 15%§ 25.8 (4–310)*†
Pawlik
200364
Retrospective 1975–2002
USA
29 angiosarcoma of the scalp 71* NR NR NR NR NR 21.9 (0–73.5)*†
Rougraff
201265
Retrospective 1992–2007
USA
381 grade 3 STS of extremity or 
lank
NR NR NR NR NR NR 66.6‡
20*
Rougraff
200669
Retrospective 1992–2003
USA
624 sarcoma:
382 soft- tissue sarcoma
NR NR NR NR NR NR NR
278 high- grade STS 73.3 (0.25–362.8)‡†
104 low- grade STS 127.4 (0.25–256)‡†
Singla
201466
Retrospective 1990–2011
USA
72 angiosarcoma 65 (19–93)*† NR NR NR NR NR 0-154.8†
41%§
Ferrari
201067
Retrospective 1977–2005 
Italy
575 STS ≤21¶ NR NR NR NR NR 8.6
(1–258)*†
Pratt
197842
Retrospective 1962–1976
USA
46 rhabdyomyosarcoma of head 
or neck
5.9 (0.3–20.5)*† NR NR NR NR NR 4.3–19.3*
Bandyopadhyay
201643
Retrospective 1991–2010
USA
391 primary pulmonary artery 
sarcoma
52 (14–94)*† NR NR NR NR NR 14.3*
Brouns
200344
Retrospective 1999–2001
Belgium
100 STS 50.5 (3–88)*† 17.2 (8.6–
1032)*†
NR NR NR 25.8 (8.6–339.7)*† NR
Chandu
200345
Retrospective 1955–1999
Scotland
109 STS 33.4
(10-77)‡†
NR NR NR NR 86‡ NR
Clark
200546
Prospective 2003–2004
UK
31 STS with referral >3 months 
(19.5%)
59 (34–84)‡† NR NR NR NR 94.6 (17.2–412.8)‡† NR
Johnson
200847
Prospective/recall
2005
UK
162 STS 53 (16–88)‡† 1.3*
28.6‡
2.4* 6.9*   25.0*
83.1‡
40.4*
112.3‡
Lawrence
198648
Retrospective 1977–1978
and 1983–1984
2355 STS and
3457 STS
>18¶ NR NR NR NR 4.3* 17.2*
Park
201049
Retrospective 1997–2008
Korea
18 grade 3 STS of the extremity 
with delay >1 year
44.8
(15-79)‡†
NR NR NR NR NR (51.6-154.8)†
Seinen
201050
Retrospective 2003–2009
Sweden
33 retroperitoneal sarcoma (1 
GIST)
66
(21-86)‡†
3.3 (0–73.1)*† 2.1
(0–34.9)*†
5.1
(0.3–160)*†
1.1 (0.1–
69)*†
13.4 (4.3–172)*† NR
Bruun
197651
Retrospective 1962–1974
Denmark
7 oral sarcoma 29
(10-81)‡†
6.9‡ NR NR NR 15.9‡ NR
Cooper
199652
Retrospective 1984–1993
Ireland
18 STS interval >4 weeks 43
(2-89)*†
36%§ 23%§ 11%§ NR 28* NR
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Author;
year
Study design, time period 
and country
Study
population Age (years)
Patient
interval (weeks)
Primary
care
interval 
(weeks)
Secondary 
care
interval 
(weeks)
Tertiary 
care 
interval 
(weeks)
Diagnostic interval 
(weeks) Total interval (weeks)
Antillon
200853
Retrospective 2000–2007
Guatemala
47 rhabdo- myosarcoma 6 (1–17)*† NR NR NR NR NR 8.6 (2–51.6)*†
33 non- rhabdo- myosarcoma 11 (2–17)*† 25.8 (3–154.8)*†
Chotel
200854
Retrospective 1985–2006
UK
33 synovial sarcoma 12.3
(3-16)‡†
43 (0–156)‡† NR NR NR 50 (0–362)‡† 98 (2–364)‡†
Durve 200455 Retrospective 1980–2000
UK
14 rhabdo- myosarcoma of ear 
and temporal bone
4.5 (1.0–8.6)‡† NR NR NR NR NR 21 (4–78)‡†
Watson 199456 Retrospective 1985–1992
Australia
40 STS of extremity 59 (14–87)*† NR NR NR NR NR 16 weeks (2-104)*†
Monnier 200657 Retrospective 1982–2002
France
66 dermatoibrosarcoma 
protuberans
43
(8-81)‡†
NR NR NR NR NR 520.1 (8.3–2115.6)‡†
Dyrop 201360 Retrospective 2007–2010
Denmark
258 STS NR NR NR NR 2007: 4* 
2010: 2.6*
NR NR
Buvarp Dyropl 201659 Retrospective 2014–2015
Denmark
545 referred patients of which: 55 (0–93)*‡ NR NR NR NR NR NR
102 sarcoma patients
(88 soft tissue
14 bone)
11* 2.4* 4.1* 2.4* NR 25.1*
George
201230
Retrospective 2011
UK
66 STS ≥18¶ 4.3 (0–516)*‡ 13.3 (1.7–
154.8)*‡
NR NR NR NR
Martin
200731
Retrospective 2001–2003
USA
38 STS 22.2 (15–29)‡† NR NR NR NR NR 24.9‡
Smith
201132
Prospective 1985–2009
UK
2366 STS 57* NR NR NR NR NR 26*
Grimer
200633
Prospective 1986–2006
UK
1460 STS NR NR NR NR NR NR 26*
Chen
201734
Retrospective 2004–2012
USA
364 malignancies of which
18 STS
14* NR NR NR NR NR 7.2*
Nandra
201527
Retrospective 1985–2010
UK
2277 STS 57* NR NR NR NR NR 26*
Desandes
201835
Retrospective 2012–2013
France
993 malignancies of which
43 STS
NR NR NR NR NR NR 22.9a
15–19† NR NR NR NR NR 15.4*
20-24† NR NR NR NR NR 48.7*
Smolle
201968
Retrospective 1982–2014
UK
248 synovial sarcomas 37† NR NR NR NR NR 52*
<16¶ NR NR NR NR NR 49.8*
≥16¶ NR NR NR NR NR 52*
Youngerl
201838
Retrospective 2015
UK
558 sarcoma of which
418 STS
64.1 (18–96) ‡† 46.8%§ NR NR NR NR NR
Table 3 Continued
Continued
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Effect of tumour-speciic factors
Three studies found no relationship between tumour 
size and length of the total interval,27 54 69 one study 
(n=575) in children and adolescents found that larger 
tumours were associated with a longer total interval 
(both for tumours <5 vs ≥5 cm and <10 vs ≥10 cm),67 
while a study in adults (n=162) reported that smaller 
tumours (median 8 cm) were associated with a longer 
total interval.47
Five studies reporting on the influence of tumour 
localisation have yielded contradictory results. Chotel et 
al (n=33) reported that synovial sarcoma of the knee or 
elbow had a longer total interval than tumours at other 
sites54 and Smolle et al found synovial sarcomas located 
superficially had a longer interval than deeply located 
tumours (n=248; 2 years vs 12 months).68 However, two 
other studies found no relationship between tumour 
site and total interval.47 69 In children and adolescents, 
Ferrari et al (n=575) reported a longer total interval for 
STS of the extremities compared with tumours at other 
sites67; the authors attributed this difference to the under-
lying tumour histology, which for extremity tumours was 
more likely to consist of non- rhabdomyosarcomas and 
thus to encompass a broad spectrum of tumour biolo-
gies including low- grade STS. There are limited data 
specifically exploring the relationship between tumour 
histology and total interval, but Nandra et al (n=2 277) 
identifed that low- grade sarcomas were associated with a 
longer total interval.27
Effect of patient-speciic factors
Patient gender, level of education and measures of social 
deprivation were not associated with length of total 
interval.47 67 The effect of patient age was examined in 
five studies. Ferrari et al (n=575) established that chil-
dren over 10 years old had a longer total interval than 
those younger than 10 years old.67 Desandes et al (n=43) 
found the same result when comparing age groups 15–19 
vs 20–24 years (15.4 vs 48.7 weeks; p=0.04).35 Smolle et 
al found no difference for patients with synovial sarcoma 
older or younger than 16 years old.68 A large retrospective 
study of almost 5000 sarcoma patients found no differ-
ence in total interval in patients older and younger than 
the median study age of 57 years.27 A Sarcoma UK survey 
(n=558) established no association between age and 
patient interval or total interval.38
Two studies in children examined the effect of 
presenting symptoms on the total interval. The first 
(n=575) found no significant difference in the length of 
total interval between patients presenting with a swelling 
or with a specific symptom (eg, urethral obstruction).67 
The second in 33 patients with synovial sarcoma found 
the presence of a lump led to a shorter doctor interval, 
while a periarticular location or presence of a joint 
contracture led to both a longer patient and a longer 
doctor interval.54
Open access
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Effect of healthcare system-related factors
The influence of the year of first presentation was studied 
in two publications, which did not find an improvement 
in total interval over the past 30–40 years.5467
In a study of 162 STS patients surveyed in 2005, the 
median patient interval was just 1.3 weeks, while the 
median primary care interval was 25.0 weeks47; if patients 
were reassured by the first medical professional they 
consulted (eg, their GP), it took twice as long to be 
referred on to an appropriate specialist centre.
Another single centre study of 545 patients with 
suspected sarcoma referred to a specialist clinic in 
Denmark reported a median total interval of 25.1 weeks59; 
102 patients (19%) had a sarcoma (88 soft tissue, 14 BS), 
68 patients (12%) had another malignancy.58 Patients 
referred to the centre with prior investigations in their 
local hospital had a longer total interval than those with 
investigations in the sarcoma centre (median 13.3 vs 23.7 
weeks). Synovial sarcoma patients with an unplanned 
resection had a longer diagnostic interval than those 
referred directly to a sarcoma centre (24 vs 12 months; 
p=0.001).68
Relationship between total interval and patient outcomes
The influence of the length of total interval on clinical 
outcomes in STS patients has been reported in 10 retro-
spective studies (table 4).27 43 54 61–63 65 67–69
Five of these studies observed no effect on 
survival.54 61 65 68 69 One study (n=2 277) reported that 
patients with STS treated between 1985 and 2010 with a 
longer total interval (26 vs 20 weeks) had a significantly 
improved survival rate, even when stratified by disease 
stage.27 This pattern was consistent for all histological 
subtypes apart from rhabdomyosarcoma where survival 
was significantly better with a short total interval (n=34, 16 
vs 52 weeks total interval). Furthermore, patients under-
going unplanned resections prior to specialist referral 
had a lower 1- year mortality rate than patients referred 
directly. These patients tended to have small, superficial, 
low- grade tumours, which are associated with a better 
prognosis.
Three studies reported that patients with a shorter 
total interval had improved overall survival rates.43 63 67 
Ferrari et al analysed the risk of death for 575 children 
at different time intervals and found worse survival with 
increased diagnostic interval and with diagnostic intervals 
<1 month vs 1–3 months (HR 1.4 (95% CI 0.7 to 2.6)) and 
<1 month vs >12 months (HR 3.6 (95% CI 1.7 to 8.0)), 
respectively.67 Bandyopadhyay et al (n=391) reported that 
the odds of death increased by 46% for every doubling of 
the diagnostic interval.43
No study has investigated the influence of the length of 
the total interval on patient- reported outcomes.
dIsCussIon
To the best of our knowledge, there is no published 
systematic review on the sarcoma total diagnostic interval. 
Analysis of the length of the total interval is complex, as 
it is influenced by many different factors. In sarcomas, 
assessment of the total interval is further challenged by 
the heterogeneity of the disease, the rarity of the group 
and the presence of 70+ subtypes.
Focusing on the patient interval, it might be antici-
pated that patients who consult a doctor early have a 
reason for doing so (eg, worrying, severe symptoms or 
evidence of rapid progression), which would result in a 
quicker referral for investigation and a shorter diagnostic 
interval16 21 and vice versa.12 13 26 54 However, some aspe-
cific symptoms such as pain have given contradictory 
results.22 26
Both patient and doctor intervals might be influenced by 
the biological behaviour of the sarcoma. The usually indo-
lent chondrosarcomas had a longer total interval than the 
more aggressive osteo and Ewing sarcomas,12 14 21 26 and 
non- rhabdomyosarcoma STS had a longer total interval 
than rhabdomyosarcomas or soft tissue ESFT.67
Furthermore, tumour location influences the length 
of the total interval, with atypical tumour presentations 
increasing the difficulties in diagnosis and prolonging 
the diagnostic interval.
There are two main findings from studies of the 
primary and secondary care intervals. First, if at initial 
presentation the assessing clinician is falsely reassured 
or makes an incorrect diagnosis, the diagnostic interval 
is severely prolonged.47 62 Second, patients undergoing 
an unplanned resection prior to referral to a specialist 
centre have a lower 1- year mortality rate than those 
referred directly to a specialist centre.27 This finding 
may be due to selection bias, as patients undergoing 
unplanned resections have smaller, superficial and lower 
grade tumours, which are known factors associated with a 
better prognosis.
The influence of the length of the total interval on clin-
ical outcomes remains unclear. It might be predicted that 
sarcomas with more aggressive behaviour have a shorter 
total interval and worse survival outcomes, while sarcomas 
with indolent behaviour have a longer total interval and 
improved survival. Alternatively, it may be expected that 
shorter total intervals lead to earlier treatment and better 
outcomes. For STS, we found conflicting results, which 
is not surprising with over 70 histological subtypes with 
different clinical behaviours. Most BS studies from our 
review not report an association between length of total 
interval and survival as well. Researchers have argued 
that this lack of an association, often referred to as the 
‘waiting- time paradox’, may be due to the fact that the 
studies have not been able to adjust for the aggressiveness 
of the tumour.
To date, the influence of total interval on morbidity, 
HRQoL and other patient- reported outcomes has not 
been assessed. Based on the available literature in other 
malignancies, improving the total interval will likely influ-
ence the level of patient satisfaction, fear and morbidity. 
The importance of these outcomes is demonstrated by 
Mesko et al who studied factors most commonly causing 
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Table 4 The inluence of length of the total interval on outcomes for STS
Ref.
Study design, time 
period and country Study population Age (years) Total interval (weeks)
Influence on stage or metastases 
at diagnosis Influence on survival
Gofman et al
200761
Retrospective
1991–2004
Israel
73 synovial sarcoma 38 (8–82)*† 77.4 (8.6–202.1)*† NR Total interval ≤1 year resulted in 
better systemic control (HR 0.3; 
p=0.037). No effect on overall 
survival.
Amant et al
200362
Retrospective
1990–2002
Belgium
15 endometrial stromal 
sarcoma
34‡ NR Stage 4 disease in 5/6 with missed 
diagnosis, compared with 1/9 in 
correct diagnosis group. No data 
on diagnostic interval in the latter 
group.
NR
6 (40%) diagnosis 
initially missed
614.9 (103.2–1754.4)‡†
Nakamura et al
201163
Retrospective
2001–2009
Japan
100 STS, referred for 
additional resection
57 (0–89)‡† 25.843–17)*‡ NR 5 years survival: 54.4%
(66.8% without metastases, 5.9% 
with metastases)
>6 months: n=43§ 12/43 metastases vs 59.7% (34 patients without 
metastases)
(p=0.04)
≤6 months: n=57§ 6/51 metastases
(p=0.048)
77% (48 patients without 
metastases)
Rougraff et al 
201265
Retrospective
1992–2007
USA
381 grade 3 STS of 
extremity or lank
NR 66.6 20‡* No association No association
Rougraff et al 
200769
Retrospective
1992–2003
USA
624 sarcoma:
382 soft tissue sarcoma
NR NR No association No association
278 high- grade STS 73.3 (0.25–362.8)‡†
104 low- grade STS 127.4 (0.25–256)‡†
Ferrari et al
201067
Retrospective
1977–2005 Italy
575 STS ≤21§ 8.6
(1-258)*†
No association Risk of death increased the longer 
the diagnostic interval (p=0.002)
Bandyopadhyay 
et al
201643
Retrospective
1991–2010
USA
391 primary pulmonary 
artery sarcoma
52 (14–94)*† 14.3* NR For every doubling diagnostic 
interval, the odds of death 
increased by 46% (p<0.001)
Chotel et al
200854
Retrospective
1985–2006
UK
33 synovial sarcoma 12.3
(3-16)‡†
98 (2–364)‡† NR No association
Nandra et al
201527
Retrospective
1985–2010
UK
2277 STS 57* NR No association 1- year mortality (13%), survivors 
longer total interval (20 vs 26 
weeks)
Smolle et al
201968
Retrospective
1982–2014
UK
248 synovial sarcomas 37‡ 52* NR No association (<1 year versus 
>1 year)
<16§ 49.8*
≥16§ 52*
Continued
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litigation in sarcoma cases in the USA.70 In 81% of cases, 
a delay in diagnosis was part of the complaint, a further 
7% were about misdiagnosis and 11% about unneces-
sary amputation. Primary care doctors and orthopaedic 
specialists were most common defendants in delay in 
diagnosis cases.
In neither BS or STS did our review identify a clear cut- 
off point for appropriate versus inappropriate length of 
total interval or its components. Apart from the contra-
dictory results in terms of influence of the length of the 
interval on survival, several other factors make it diffi-
cult to draw firm conclusions. First, the design of most 
studies was retrospective, increasing the chance of recall 
bias with regard to self- reported outcomes such as dates 
of first symptoms. Second, many studies included a small 
number of heterogeneous patients, which made them 
unsuitable for subtype analysis. Although we excluded 
case reports, we included case series because they reflect 
the sort of research that has been done in this area, and 
show how heterogeneous the population is. Third, the 
inclusion criteria of studies differed; some studies only 
considered those patients who reported a diagnostic 
delay, which made it impossible to compare this group 
to the entire sarcoma population. Furthermore, diag-
nostic delay was defined differently throughout the 
literature. One of the limitations of this review is that we 
had to work with these different definitions,which made 
comparisons difficult. We propose for future reports that 
the date of pathological diagnosis is used as the endpoint 
of the diagnostic interval. Furthermore, studies included 
in this review were conducted over the past 50 years. 
During this period, radiological and histological diag-
nostic techniques have evolved, treatment options have 
improved, and, in some countries, diagnostic pathways 
with referrals of suspected lumps to centralised sarcoma 
services have developed, which may have influenced our 
results.
Centralised sarcoma care may improve diagnostic 
pathways and there is an increasing number of (inter) 
national guidelines for the diagnosis and management of 
sarcomas.71–74 Centralising care at sarcoma centres with 
a multidisciplinary team improves the diagnostic interval 
because patients (1) do not lose time at local hospitals, 
(2) receive appropriate imaging for tumour staging and 
(3) get a higher rate of correct preoperative pathologic 
diagnosis.10 12 29 30 50 58 75–79 Improvement of these factors 
decrease tumour size and stage at diagnosis, resulting in 
an increase of the quality of surgery and improvement 
of survival outcomes in several of these studies.60 75 77–80 
Best practices of different countries could be integrated 
to develop the optimal diagnostic pathway. In order for 
such guidelines to be successfully implemented, one 
needs strong political support with continuous attention 
to raise awareness and optimise the system by following a 
quality and control cycle.60
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ConClusIon
This review confirms the complexity of the total interval 
to sarcoma diagnosis. Published studies give contradictory 
results in terms of determinants for a long total interval 
as well as its influence on outcomes. The impact of a long 
interval on HRQoL has not been studied. To present a 
clinically relevant cut- off point that discriminates between 
a short or long interval is thus impossible. Such a cut- off 
point, which can differ between histological subtypes, 
is necessary to make guidelines more evidence based, 
help to guide patients and support the sarcoma diag-
nostic process. Furthermore, to improve care we need to 
understand the impact of the total interval on HRQoL 
of patients diagnosed with a sarcoma. Future research 
should include relevant outcomes for patients, as well 
as focus on areas where a change in management could 
make a difference, such as in increased public awareness, 
education of primary and secondary healthcare providers 
and improved access to specialist centres.
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